444 Alaska Avenue
Suite #BAA205 Torrance, CA 90503 USA
+1 424 999 9627
24/7 Customer Support
sales@markwideresearch.com
Email us at
Granulomatosis With Polyangiitis Diagnosis Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2025-2034
Published Date: May, 2025
Base Year: 2024
Delivery Format: PDF+Excel, PPT
Historical Year: 2018-2023
No of Pages: 263
Forecast Year: 2025-2034
Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, is a rare autoimmune disorder that causes inflammation in blood vessels and affects multiple organs. GPA mainly affects the upper and lower respiratory tract, kidneys, and skin. The diagnosis of GPA is challenging, as the symptoms are often non-specific and can resemble those of other diseases. The disease is more prevalent in Caucasians and usually affects people between the ages of 40 and 60 years.
The granulomatosis with polyangiitis diagnosis market is driven by the increasing prevalence of autoimmune diseases, advances in diagnostic technologies, and growing awareness among patients and healthcare professionals. The global granulomatosis with polyangiitis diagnosis market size was valued at USD 492.2 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 5.6% from 2021 to 2028.
Granulomatosis with polyangiitis (GPA), also known as Wegener’s granulomatosis, is a rare autoimmune disorder that affects multiple organs in the body. The disease is characterized by inflammation in blood vessels, which can lead to tissue damage and organ dysfunction. The disease mainly affects the respiratory system, kidneys, and skin.
The diagnosis of GPA is challenging, as the symptoms are often non-specific and can resemble those of other diseases. The disease is more prevalent in Caucasians and usually affects people between the ages of 40 and 60 years. The early diagnosis of GPA is critical for effective treatment and management of the disease.
Executive Summary:
The global granulomatosis with polyangiitis diagnosis market is expected to grow at a CAGR of 5.6% from 2021 to 2028. The market is driven by the increasing prevalence of autoimmune diseases, advances in diagnostic technologies, and growing awareness among patients and healthcare professionals.
The market is segmented by diagnostic technology, end-user, and region. The diagnostic technology segment is further segmented into laboratory tests, imaging tests, and biopsy. The end-user segment is further segmented into hospitals, diagnostic laboratories, and research centers.
North America dominated the granulomatosis with polyangiitis diagnosis market in 2020, accounting for the largest revenue share. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing prevalence of autoimmune diseases, rising healthcare expenditure, and growing awareness among patients and healthcare professionals.
Important Note: The companies listed in the image above are for reference only. The final study will cover 18–20 key players in this market, and the list can be adjusted based on our client’s requirements.
Key Market Insights:
The global granulomatosis with polyangiitis diagnosis market is driven by the increasing prevalence of autoimmune diseases, advances in diagnostic technologies, and growing awareness among patients and healthcare professionals. The market is expected to grow at a CAGR of 5.6% from 2021 to 2028.
The market is segmented by diagnostic technology, end-user, and region. The diagnostic technology segment is further segmented into laboratory tests, imaging tests, and biopsy. The end-user segment is further segmented into hospitals, diagnostic laboratories, and research centers.
North America dominated the granulomatosis with polyangiitis diagnosis market in 2020, accounting for the largest revenue share. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing prevalence of autoimmune diseases, rising healthcare expenditure, and growing awareness among patients and healthcare professionals.
Market Analysis:
The global granulomatosis with polyangiitis diagnosis market size was valued at USD 492.2 million in 2020 and is expected to grow at a CAGR of 5.6% from 2021 to 2028. The market is driven by the increasing prevalence of autoimmune diseases, advances in diagnostic technologies, and growing awareness among patients and healthcare professionals.
The market is segmented by diagnostic technology, end-user, and region. The diagnostic technology segment is further segmented into laboratory tests, imaging tests, and biopsy. The laboratory tests segment is expected to hold the largest market share during the forecast period, owing to the increasing use of laboratory tests for the diagnosis of autoimmune diseases.
The end-user segment is further segmented into hospitals, diagnostic laboratories, and research centers. The hospitals segment is expected to hold the largest market share during the forecast period, owing to the increasing number of hospitalizations for the treatment of autoimmune diseases.
North America dominated the granulomatosis with polyangiitis diagnosis market in 2020, accounting for the largest revenue share. The dominance of the North American region can be attributed to the increasing prevalence of autoimmune diseases, rising healthcare expenditure, and growing awareness among patients and healthcare professionals.
Europe is expected to hold the second-largest market share during the forecast period, owing to the presence of well-established healthcare infrastructure and increasing government initiatives to promote early diagnosis and treatment of autoimmune diseases.
The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing prevalence of autoimmune diseases, rising healthcare expenditure, and growing awareness among patients and healthcare professionals.
Market Drivers:
- Increasing Prevalence of Autoimmune Diseases: The increasing prevalence of autoimmune diseases is expected to drive the growth of the granulomatosis with polyangiitis diagnosis market. According to the American Autoimmune Related Diseases Association (AARDA), approximately 50 million Americans suffer from autoimmune diseases, and the prevalence is increasing every year.
- Advances in Diagnostic Technologies: The advances in diagnostic technologies are expected to drive the growth of the granulomatosis with polyangiitis diagnosis market. The availability of advanced diagnostic technologies, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET), has improved the accuracy of diagnosis and reduced the risk of misdiagnosis.
- Growing Awareness among Patients and Healthcare Professionals: The growing awareness among patients and healthcare professionals about autoimmune diseases and the importance of early diagnosis and treatment is expected to drive the growth of the granulomatosis with polyangiitis diagnosis market. The increasing availability of educational resources and support groups has also contributed to the growing awareness.
Market Restraints:
- High Cost of Diagnostic Tests: The high cost of diagnostic tests is expected to restrain the growth of the granulomatosis with polyangiitis diagnosis market. The cost of diagnostic tests, such as MRI, CT, and PET, is high, which limits their accessibility to a large population.
- Lack of Skilled Healthcare Professionals: The lack of skilled healthcare professionals is expected to restrain the growth of the granulomatosis with polyangiitis diagnosis market. The diagnosis and treatment of autoimmune diseases require specialized skills and knowledge, which are often lacking in healthcare professionals.
Market Opportunities:
- Increasing Investment in Research and Development: The increasing investment in research and development is expected to create opportunities in the granulomatosis with polyangiitis diagnosis market. The development of new diagnostic technologies and the discovery of new biomarkers for the diagnosis of autoimmune diseases is expected to drive the growth of the market.
- Emerging Markets: The emerging markets, such as the Asia Pacific and Latin America regions, are expected to create opportunities in the granulomatosis with polyangiitis diagnosis market. The increasing prevalence of autoimmune diseases in these regions and the improving healthcare infrastructure are expected to drive the growth of the market.
Market Dynamics:
- Drivers: The increasing prevalence of autoimmune diseases, advances in diagnostic technologies, and growing awareness among patients and healthcare professionals are the major drivers of the granulomatosis with polyangiitis diagnosis market.
- Restraints: The high cost of diagnostic tests and the lack of skilled healthcare professionals are the major restraints of the granulomatosis with polyangiitis diagnosis market.
- Opportunities: The increasing investment in research and development and the emerging markets are the major opportunities for the granulomatosis with polyangiitis diagnosis market.
Regional Analysis:
The granulomatosis with polyangiitis diagnosis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
North America dominated the granulomatosis with polyangiitis diagnosis market in 2020, accounting for the largest revenue share. The dominance of the North American region can be attributed to the increasing prevalence of autoimmune diseases, rising healthcare expenditure, and growing awareness among patients and healthcare professionals.
Europe is expected to hold the second-largest market share during the forecast period, owing to the presence of well-established healthcare infrastructure and increasing government initiatives to promote early diagnosis and treatment of autoimmune diseases.
The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing prevalence of autoimmune diseases, rising healthcare expenditure, and growing awareness among patients and healthcare professionals.
Latin America and the Middle East and Africa regions are expected to grow at a moderate pace during the forecast period, owing to the increasing government initiatives to improve healthcare infrastructure and the growing awareness among patients and healthcare professionals.
Competitive Landscape:
Leading companies in the Granulomatosis With Polyangiitis Diagnosis Market:
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers AG
- Abbott Laboratories
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories, Inc.
- Quest Diagnostics Incorporated
- EUROIMMUN AG (PerkinElmer, Inc.)
- F. Hoffmann-La Roche Ltd
- Inova Diagnostics, Inc.
- Menarini Diagnostics Ltd
Please note: This is a preliminary list; the final study will feature 18–20 leading companies in this market. The selection of companies in the final report can be customized based on our client’s specific requirements.
Segmentation:
The granulomatosis with polyangiitis diagnosis market is segmented by diagnostic technology, end-user, and region.
By Diagnostic Technology:
- Laboratory Tests
- Imaging Tests
- Biopsy
By End-User:
- Hospitals
- Diagnostic Laboratories
- Research Centers
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Category-wise Insights:
By Diagnostic Technology:
The laboratory tests segment is expected to hold the largest market share during the forecast period, owing to the increasing use of laboratory tests for the diagnosis of autoimmune diseases.
By End-User:
The hospitals segment is expected to hold the largest market share during the forecast period, owing to the increasing number of hospitalizations for the treatment of autoimmune diseases.
By Region:
North America dominated the granulomatosis with polyangiitis diagnosis market in 2020, accounting for the largest revenue share.
Key Benefits for Industry Participants and Stakeholders:
- Comprehensive analysis of the granulomatosis with polyangiitis diagnosis market and its segments
- Market trends, drivers, and restraints are identified to help stakeholders make informed decisions
- Competitive landscape of the granulomatosis with polyangiitis diagnosis market is analyzed to help stakeholders understand the competition in the market
- Strategies of key players are analyzed and insights are provided to help stakeholders understand the business strategies of their competitors
SWOT Analysis:
Strengths:
- Increasing prevalence of autoimmune diseases
- Advances in diagnostic technologies
- Growing awareness among patients and healthcare professionals
Weaknesses:
- High cost of diagnostic tests
- Lack of skilled healthcare professionals
Opportunities:
- Increasing investment in research and development
- Emerging markets
Threats:
- Stringent regulatory requirements
- Competition from established players
Market Key Trends:
- Increasing use of laboratory tests for the diagnosis of autoimmune diseases
- Growing adoption of advanced diagnostic technologies
- Rising demand for early diagnosis and treatment of autoimmune diseases
- Increasing government initiatives to promote early diagnosis and treatment of autoimmune diseases
Covid-19 Impact:
The Covid-19 pandemic has had a significant impact on the granulomatosis with polyangiitis diagnosis market. The pandemic has led to the postponement of non-urgent medical procedures, which has affected the diagnosis and treatment of autoimmune diseases. The pandemic has also disrupted the supply chain of diagnostic tests, leading to shortages and delays in the delivery of diagnostic tests. However, the increasing focus on the development of rapid diagnostic tests for Covid-19 is expected to drive the growth of the granulomatosis with polyangiitis diagnosis market in the long term.
Key Industry Developments:
- In March 2021, F. Hoffmann-La Roche Ltd. announced the launch of its cobas Cdiff test for the detection of Clostridium difficile infection.
- In November 2020, Thermo Fisher Scientific Inc. announced the launch of its Oncomine Precision Assay, a pan-cancer next-generation sequencing assay for the detection of genetic variants in cancer patients.
Analyst Suggestions:
- Focus on the development of new diagnostic technologies for the early diagnosis and treatment of autoimmune diseases.
- Increase investment in research and development to discover new biomarkers for the diagnosis of autoimmune diseases.
- Collaborate with hospitals, diagnostic laboratories, and research centers to improve the accessibility and affordability of diagnostic tests.
Future Outlook:
The global granulomatosis with polyangiitis diagnosis market is expected to grow at a CAGR of 5.6% from 2021 to 2028. The market is driven by the increasing prevalence of autoimmune diseases, advances in diagnostic technologies, and growing awareness among patients and healthcare professionals. The laboratory tests segment is expected to hold the largest market share during the forecast period, owing to the increasing use of laboratory tests for the diagnosis of autoimmune diseases. North America dominated the granulomatosis with polyangiitis diagnosis market in 2020, accounting for the largest revenue share. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing prevalence of autoimmune diseases, rising healthcare expenditure, and growing awareness among patients and healthcare professionals.
Conclusion:
The granulomatosis with polyangiitis diagnosis market is expected to grow at a significant pace during the forecast period. The increasing prevalence of autoimmune diseases, advances in diagnostic technologies, and growing awareness among patients and healthcare professionals are the major drivers of the market. The market is highly competitive, with the presence of several established players.
North America dominated the granulomatosis with polyangiitis diagnosis market in 2020, accounting for the largest revenue share. The dominance of the North American region can be attributed to the increasing prevalence of autoimmune diseases, rising healthcare expenditure, and growing awareness among patients and healthcare professionals.
Granulomatosis With Polyangiitis Diagnosis Market
| Segmentation | Details |
|---|---|
| Test Type | Blood Tests, Biopsy, Imaging Tests, Urine Tests, Others |
| End-User | Hospitals, Diagnostic Centers, Research Institutes |
| Region | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Please note: The segmentation can be entirely customized to align with our client’s needs.
Leading companies in the Granulomatosis With Polyangiitis Diagnosis Market:
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers AG
- Abbott Laboratories
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories, Inc.
- Quest Diagnostics Incorporated
- EUROIMMUN AG (PerkinElmer, Inc.)
- F. Hoffmann-La Roche Ltd
- Inova Diagnostics, Inc.
- Menarini Diagnostics Ltd
Please note: This is a preliminary list; the final study will feature 18–20 leading companies in this market. The selection of companies in the final report can be customized based on our client’s specific requirements.
North America
o US
o Canada
o Mexico
Europe
o Germany
o Italy
o France
o UK
o Spain
o Denmark
o Sweden
o Austria
o Belgium
o Finland
o Turkey
o Poland
o Russia
o Greece
o Switzerland
o Netherlands
o Norway
o Portugal
o Rest of Europe
Asia Pacific
o China
o Japan
o India
o South Korea
o Indonesia
o Malaysia
o Kazakhstan
o Taiwan
o Vietnam
o Thailand
o Philippines
o Singapore
o Australia
o New Zealand
o Rest of Asia Pacific
South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
The Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Israel
o Kuwait
o Oman
o North Africa
o West Africa
o Rest of MEA
Important Questions Covered in this Study
- Which are the main companies that are currently operating within the market?
- What are the factors that are predicted to propel the growth of the market?
- What are the factors that are expected to limit the growth of the market?
- Which company had the largest market share?
- What are the main opportunities available in the market?
- What are the market size and growth rates of the various segments within the market?
- What are the market sizes and growth rates of the overall market or specific regions ?
- Which region or segment is projected to be the primary driver of market growth during the forecast period?
- What are the significant trends observed in the market?
Why Choose MWR ?
Quality Research
Our goal is to provide high-quality data that stimulates growth and creates a win-win situations.
Unlimited User Access
We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions.
Free Company Inclusion
We give you an option to include 3-4 additional company players of your choice in our report without any extra charges.
Post Sale Assistance
Unlimited post sales service with an account manager dedicated to making sure that all your needs are met.
Covid-19 Impact Analysis
All our research report includes latest Covid-19 Impact and its analysis.
Client Associated with us
GET A FREE SAMPLE REPORT
This free sample study provides a complete overview of the report, including executive summary, market segments, competitive analysis, country level analysis and more.
Client Testimonials
GET A FREE SAMPLE REPORT
This free sample study provides a complete overview of the report, including executive summary, market segments, competitive analysis, country level analysis and more.